[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355441-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-355441-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pivotal-role-of-long-non-coding-rna-in-the-development-of-new-therapeutic-approaches-for-plural-mesothelioma-review","Pivotal role of long non-coding RNA in the development of new therapeutic approaches for plural mesothelioma - Review","","Pleural mesothelioma is a rare, aggressive tumor affecting the pleural lining, representing about 90% of all mesotheliomas. Diagnosis often occurs 30–40 years after asbestos exposure, so patients present at late stages, resulting in poor outcomes with median survival around one year and a 5% 5-year survival rate. Current care typically combines platinum-based chemotherapy, antifolates, surgery, and radiotherapy, but improved survival remains necessary. Long non-coding RNAs (over 200 nucleotides) regulate cellular processes; dysregulation can initiate cancers and increase aggressiveness. This review summarizes lncRNA roles in pleural mesothelioma pathogenesis and their potential therapeutic targets.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pivotal-role-of-long-non-coding-rna-in-the-development-of-new-therapeutic-approaches-for-plural-mesothelioma-review/355441/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pivotal-role-of-long-non-coding-rna-in-the-development-of-new-therapeutic-approaches-for-plural-mesothelioma-review/355441.png","ImageObject",300,407,{"name":42,"@type":43},"Sophia Brooks","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is pleural mesothelioma prognosis generally poor?","Question",{"text":63,"@type":64},"Diagnosis typically occurs 30–40 years after asbestos exposure, leading to late-stage detection. The median survival is about 9–12 months with only around a 5% chance of 5-year survival.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What current standard treatments are discussed for pleural mesothelioma?",{"text":68,"@type":64},"Treatment is described as multimodal, combining platinum-based chemotherapy with antifolates, radiotherapy, and surgery. Chemoresistance remains a key challenge.",{"name":70,"@type":61,"acceptedAnswer":71},"How might long non-coding RNAs (lncRNAs) contribute to therapy development?",{"text":72,"@type":64},"LncRNAs participate in diverse cellular processes and biological mechanisms. When dysregulated, they can alter pathways that initiate cancers or promote aggressiveness, making them potential therapeutic targets in pleural mesothelioma.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},355441,1790835448,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962084925636,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Kiriacos et al. Discover Oncology (2026) 17:546 [https://doi.org/10.1007/s12672-026-04677-y](https://doi.org/10.1007/s12672-026-04677-y)  \nDiscover Oncology  \nREVIEW Open Access  \nPivotal role of long non-coding RNA in the  development of new therapeutic approaches for plural mesothelioma  \nCaroline Joseph Kiriacos2, Dina M. Elkahwagy3 and Manar Mansour1*  \n*Correspondence:  \nManar Mansour [manar.soliman@guc.edu.eg](manar.soliman@guc.edu.eg)[ ](manar.soliman@guc.edu.eg)1Pharmaceutical Biology and Microbiology Department, Faculty of Pharmacy and Biotechnology, The German University in Cairo (GUC), Main Entrance Fifth Settlement, Cairo, Egypt 2Microbiology and Immunology Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt 3Pharmaceutical Biology Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt  \nAbstract  \nPleural mesothelioma is a rare aggressive tumor that affects the parietal layer of thepleura. It constitutes 90% of mesotheliomas. Usually, the diagnosis takes place 30 to 40 years after asbestos exposure. Thus, patients are diagnosed at a very late stage, leading to a poor prognosis, with a low median survival rate of approximately one year and a 5-year survival rate of only 5% . The available treatment usually consists of a multimodal approach, including chemotherapy (platinum-based drugs and antifolates), surgery, and radiotherapy. Yet, new therapeutic approaches are still needed to achieve higher survival rates. Long non-coding RNAs are transcripts of more than 200 nucleotides and have been proven to participate in various cellular processes and biological mechanisms. Upon dysregulation, many biological pathways can be affected, initiating cancers or even promoting their aggressiveness. These non-coding RNAs have been studied for their therapeutic potential in various cancers. The role of long non-coding RNAs in PM, whether in regulating pathogenicity or as potential therapeutic targets, requires further investigation. This review highlights the role of lncRNAs in PM pathogenesis and their potential as therapeutic targets.  \n1 Introduction  \nMesothelioma, a highly aggressive rare tumor, targets the serosal surface, specifically the mesothelial lining of the pericardium, peritoneum, tunica vaginalis, and pleura [1]. Pleural mesothelioma (PM) is the most prevalent, accounting for over 90% of cases [2, 3]. Previously, the WHO classified this as malignant pleural mesothelioma. However, in 2021, the WHO dropped the prefix ‘malignant as all mesotheliomas are by default considered malignant, whether localized or diffuse [4]. Figure 1 [5, 6] highlights the different types of mesothelioma and their respective percentages.  \nPleural mesothelioma comprises morphological differentiation; therefore, it is divided into three histologic subtypes: epithelioid, sarcomatoid, and biphasic [7]. Although any subtype of this cancer is aggressive, the epithelioid subtype has a better prognosis than the other subtypes [8]. Sarcomatoid holds the worst prognosis [8, 9].  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by","cbCaikx8oos77ck4","https://ap.wps.com/l/cbCaikx8oos77ck4","pdf",1843660,25,"English","# Abstract\n# 1 Introduction\n## 1.1 Treatment","[{\"question\":\"Why is pleural mesothelioma prognosis generally poor?\",\"answer\":\"Diagnosis typically occurs 30–40 years after asbestos exposure, leading to late-stage detection. The median survival is about 9–12 months with only around a 5% chance of 5-year survival.\"},{\"question\":\"What current standard treatments are discussed for pleural mesothelioma?\",\"answer\":\"Treatment is described as multimodal, combining platinum-based chemotherapy with antifolates, radiotherapy, and surgery. Chemoresistance remains a key challenge.\"},{\"question\":\"How might long non-coding RNAs (lncRNAs) contribute to therapy development?\",\"answer\":\"LncRNAs participate in diverse cellular processes and biological mechanisms. When dysregulated, they can alter pathways that initiate cancers or promote aggressiveness, making them potential therapeutic targets in pleural mesothelioma.\"}]","Pivotal role of long non-coding RNA in the development of new therapeutic approaches for plural mesothelioma - Review | PDF",1790118920,63,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/88b5a593450510887e5ac6433419a3dd.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8a56d4127ed66d802765caba00579f4f.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ed8a48336523beff3e7c18e55891072c.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/65944ca636f12c627114f653d6d22df1.webp",980,1306]